Literature DB >> 25812936

Structural MRI biomarkers of shared pathogenesis in autism spectrum disorder and epilepsy.

Karen Blackmon1.   

Abstract

Etiological factors that contribute to a high comorbidity between autism spectrum disorder (ASD) and epilepsy are the subject of much debate. Does epilepsy cause ASD or are there common underlying brain abnormalities that increase the risk of developing both disorders? This review summarizes evidence from quantitative MRI studies to suggest that abnormalities of brain structure are not necessarily the consequence of ASD and epilepsy but are antecedent to disease expression. Abnormal gray and white matter volumes are present prior to onset of ASD and evident at the time of onset in pediatric epilepsy. Aberrant brain growth trajectories are also common in both disorders, as evidenced by blunted gray matter maturation and white matter maturation. Although the etiological factors that explain these abnormalities are unclear, high heritability estimates for gray matter volume and white matter microstructure demonstrate that genetic factors assert a strong influence on brain structure. In addition, histopathological studies of ASD and epilepsy brain tissue reveal elevated rates of malformations of cortical development (MCDs), such as focal cortical dysplasia and heterotopias, which supports disruption of neuronal migration as a contributing factor. Although MCDs are not always visible on MRI with conventional radiological analysis, quantitative MRI detection methods show high sensitivity to subtle malformations in epilepsy and can be potentially applied to MCD detection in ASD. Such an approach is critical for establishing quantitative neuroanatomic endophenotypes that can be used in genetic research. In the context of emerging drug treatments for seizures and autism symptoms, such as rapamycin and rapalogs, in vivo neuroimaging markers of subtle structural brain abnormalities could improve sample stratification in human clinical trials and potentially extend the range of patients that might benefit from treatment. This article is part of a Special Issue entitled "Autism and Epilepsy".
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autism spectrum disorder; Epilepsy; Focal cortical dysplasia; Magnetic resonance imaging; Malformations of cortical development; Mammalian target of rapamycin (mTOR)

Mesh:

Substances:

Year:  2015        PMID: 25812936     DOI: 10.1016/j.yebeh.2015.02.017

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  6 in total

1.  Parent-Reported Developmental Regression in Autism: Epilepsy, IQ, Schizophrenia Spectrum Symptoms, and Special Education.

Authors:  Kenneth D Gadow; Greg Perlman; Rebecca J Weber
Journal:  J Autism Dev Disord       Date:  2017-04

2.  Multidimensional Neuroanatomical Subtyping of Autism Spectrum Disorder.

Authors:  Seok-Jun Hong; Sofie L Valk; Adriana Di Martino; Michael P Milham; Boris C Bernhardt
Journal:  Cereb Cortex       Date:  2018-10-01       Impact factor: 5.357

Review 3.  Studying Autism Spectrum Disorder with Structural and Diffusion Magnetic Resonance Imaging: A Survey.

Authors:  Marwa M T Ismail; Robert S Keynton; Mahmoud M M O Mostapha; Ahmed H ElTanboly; Manuel F Casanova; Georgy L Gimel'farb; Ayman El-Baz
Journal:  Front Hum Neurosci       Date:  2016-05-11       Impact factor: 3.169

Review 4.  Pediatric Traumatic Brain Injury and Autism: Elucidating Shared Mechanisms.

Authors:  Rahul Singh; Ryan C Turner; Linda Nguyen; Kartik Motwani; Michelle Swatek; Brandon P Lucke-Wold
Journal:  Behav Neurol       Date:  2016-12-15       Impact factor: 3.342

Review 5.  Epilepsy in patients with autism: links, risks and treatment challenges.

Authors:  Frank Mc Besag
Journal:  Neuropsychiatr Dis Treat       Date:  2017-12-18       Impact factor: 2.570

Review 6.  Quantitative magnetic resonance imaging traits as endophenotypes for genetic mapping in epilepsy.

Authors:  Saud Alhusaini; Christopher D Whelan; Sanjay M Sisodiya; Paul M Thompson
Journal:  Neuroimage Clin       Date:  2016-09-08       Impact factor: 4.881

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.